AstraZeneca stock dropped as its breast cancer drug missed the mark in a study. The antibody drug conjugate didn't show significant improvement in overall survival vs. chemotherapy. This setback surprised Wall Street analysts. Gilead Sciences' rival drug saw a slight increase in its stock.